文献速递乳腺癌

紫杉类化疗联合或不联合Indoximod治疗转移性乳腺癌的随机临床试验

Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项2期双盲随机安慰剂对照试验在ERBB2阴性转移性乳腺癌患者中比较紫杉类联合Indoximod或安慰剂一线治疗,共164例接受治疗。结果显示Indoximod组与安慰剂组的中位PFS分别为6.8个月和9.5个月(HR 1.2,95%CI 0.8-1.8),差异无统计学意义,因缺乏疗效研究终止。

要点

  • 在ERBB2阴性转移性乳腺癌中,Indoximod联合紫杉类未改善PFS。
  • Indoximod组与安慰剂组中位PFS分别为6.8个月和9.5个月(HR 1.2)。
  • 两组中位OS分别为19.5个月和20.6个月,差异无统计学意义。

核心结论

  • 在ERBB2阴性转移性乳腺癌患者中,紫杉类联合Indoximod对比紫杉类联合安慰剂未改善无进展生存期。

研究设计与样本

  • 2期双盲随机1:1安慰剂对照临床试验,2013年8月26日至2016年1月25日在多个国际中心入组。
  • 169例随机,164例接受治疗(Indoximod组85例,安慰剂组79例)。
  • 研究因缺乏疗效于2017年6月终止。

主要发现

  • 中位PFS Indoximod组6.8个月(95%CI 4.8-8.9),安慰剂组9.5个月(95%CI 7.8-11.2),HR 1.2(95%CI 0.8-1.8)。
  • 中位OS Indoximod组19.5个月,安慰剂组20.6个月,差异无统计学意义。
  • ≥3级治疗中出现的不良事件两组均为60%。
  • 中位随访时间17.4个月(范围0.1-39.4)。

关键数值与推荐

  • 入组标准包括ERBB2阴性转移性乳腺癌、可接受紫杉类治疗、体能状态良好、器官功能正常、无既往免疫治疗史、无自身免疫病。
  • 干预方案为紫杉类(紫杉醇80 mg/m2每周,用3周停1周;或多西他赛75 mg/m2每3周)联合安慰剂或Indoximod 1200 mg口服每日两次,作为一线治疗。

临床怎么用

  • 该研究未显示在紫杉类基础上加用Indoximod的临床获益,不支持该联合方案用于ERBB2阴性转移性乳腺癌的一线治疗。

局限性

  • 研究因缺乏疗效提前终止,实际入组治疗例数(164例)低于计划样本量(154例可检测HR 0.64,但实际随机169例)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Indoleamine 2,3-dioxygenase 1 (IDO1) causes tumor immune suppression. The IDO1 pathway inhibitor indoximod combined with a taxane in patients with ERBB2-negative metastatic breast cancer was tested in a prospective clinical trial. OBJECTIVE: To assess clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 double-blinded randomized 1:1 placebo-controlled clinical trial enrolled patients at multiple international centers from August 26, 2013, to January 25, 2016. Eligibility criteria included ERBB2-negative metastatic breast cancer, ability to receive taxane therapy, good performance status, normal organ function, no previous immunotherapy use, and no autoimmune disease. The study was discontinued in June 2017 because of lack of efficacy. Data analysis was performed from February 2019 to April 2020. INTERVENTIONS: A taxane (paclitaxel [80 mg/m2] weekly 3 weeks on, 1 week off, or docetaxel [75 mg/m2] every 3 weeks) plus placebo or indoximod (1200 mg) orally twice daily as first-line treatment. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS); secondary end points were median overall survival, objective response rate, and toxic effects. A sample size of 154 patients would detect a hazard ratio of 0.64 with 1-sided α = .1 and β = .2 after 95 events. Archival tumor tissue was stained with immunohistochemistry for IDO1 expression as an exploratory analysis. RESULTS: Of 209 patients enrolled, 169 were randomized and 164 were treated (85 in the indoximod arm; 79 in the placebo arm). The median (range) age was 58 (29-85) years; 166 (98.2%) were female, and 135 (79.9%) were White. The objective response rate was 40% and 37%, respectively (indoximod vs placebo) (P = .74). The median (range) follow-up time was 17.4 (0.1-39.4) months. The median PFS was 6.8 months (95% CI, 4.8-8.9) in the indoximod arm and 9.5 months (95% CI, 7.8-11.2) in the placebo arm (hazard ratio, 1.2; 95% CI, 0.8-1.8). Differences between the experimental and placebo arms in median PFS (6.8 vs 9.5 months) and overall survival (19.5 vs 20.6 months) were not statistically significant. Grade 3 or greater treatment-emergent adverse events occurred in 60% of patients in both arms. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that, among patients with ERBB2-negative metastatic breast cancer, addition of indoximod to a taxane did not improve PFS compared with a taxane alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01792050.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mariotti V, Han H, Ismail-Khan R, et al. Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33151286. doi:10.1001/jamaoncol.2020.5572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。